|
WO2021046260A1
|
|
Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates
|
|
WO2020257275A1
|
|
Improved in vitro transcription purification platform
|
|
US2020297634A1
|
|
Method of making lipid-encapsulated rna nanoparticles
|
|
WO2020118239A1
|
|
Modified proteins and associated methods of treatment
|
|
US2020181584A1
|
|
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
WO2020033748A1
|
|
Compositions and agents against nonalcoholic steatohepatitis
|
|
EP3773476A1
|
|
Lipid particles for nucleic acid delivery
|
|
US2019002906A1
|
|
Synthesis and structure of high potency rna therapeutics
|
|
EP3630200A1
|
|
Therapeutics for phenylketonuria
|
|
EP3589290A1
|
|
Translatable molecules and synthesis thereof
|
|
US2018222863A1
|
|
Ionizable cationic lipid for RNA delivery
|
|
US2018170866A1
|
|
Ionizable cationic lipid for RNA delivery
|
|
US2018105551A1
|
|
Trinucleotide MRNA cap analogs
|
|
US2017137821A1
|
|
Molecules and agents for treating hepatitis b virus
|
|
US2017190661A1
|
|
Aromatic ionizable cationic lipid
|
|
US2018169268A1
|
|
Ionizable cationic lipid for RNA delivery
|
|
CA3002647A1
|
|
Allele selective gene editing and uses thereof
|
|
WO2017027814A1
|
|
Una oligomeric agents for stimulating cystic fibrosis transmembrane conductance regulator and uses thereof
|
|
EP3328439A1
|
|
Multiligand agent for drug delivery
|
|
WO2017015671A1
|
|
Compositions for treating amyloidosis
|
